Search results
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 21 hours agoPfizer is competing against GSK's Arexvy, which hit the market about the same time in 2023. Moderna...
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with...
Morningstar· 17 hours agoPfizer Inc. (NYSE: PFE) today announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin ...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 20 hours agoModerna will rival Pfizer and GSK, which launched their shots last year. Also, in June, Moderna and...
FDA vaccine advisers vote unanimously in favor of updated COVID-19 shot for fall
WPTZ Burlington· 7 days agoThe Food and Drug Administration’s committee of independent advisers voted unanimously Wednesday to...
Another COVID vaccine? Yes, and here’s why
Denver Post· 2 days agoWhen compared against results from the original shot, the benefit of the new shot may seem modest. That’s because the original vaccines were given to a...
US FDA expands GSK's RSV vaccine approval to adults aged 50 to 59
Reuters via Yahoo News· 6 days agoThe shot, branded Arexvy, and vaccines from rivals Pfizer and Moderna are already approved for...
COVID-flu combo vaccine shows ‘positive’ results in phase 3 trials, Moderna says: A 'two-for' option
Fox News via Yahoo News· 3 days agoModerna, which is developing a combination COVID-flu vaccine, announced on Monday that in phase 3...
Moderna price target raised at Oppenheimer after RSV vaccine approval By Investing.com
Investing.com· 1 day agoModerna price target raised at Oppenheimer after RSV vaccine approval
FDA panel recommends new COVID-19 vaccine formula for fall
United Press International via Yahoo News· 7 days agoA U.S. Food and Drug Administration advisory panel on Wednesday recommended updating the formula for...
Pfizer's Paxlovid fails as 15-day treatment for long COVID, study finds
FOX Business· 5 days agoA 15-day course of Pfizer's COVID-19 antiviral treatment Paxlovid did not relieve symptoms of long...
